Valuation: Veradermics, Incorporated

Market Cap 6.01B 5.37B 4.94B 4.48B 8.5B 564B 8.71B 59.09B 23.55B 302B 22.57B 22.09B 951B P/E 2026 *
-50.3x
P/E 2027 * -54.5x
Enterprise Value 6.01B 5.37B 4.94B 4.48B 8.5B 564B 8.71B 59.09B 23.55B 302B 22.57B 22.09B 951B EV / Sales 2026 *
-
EV / Sales 2027 * 695x
Free-Float
97.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Veradermics, Incorporated

1 day+3.73%
1 week+11.13%
Current month+3.05%
1 month+9.97%
3 months+25.84%
6 months+35.62%
1 week 125.34
Extreme 125.34
145.48
1 month 106.51
Extreme 106.51
146.58
Current year 32
Extreme 32
146.58
1 year 32
Extreme 32
146.58
3 years 32
Extreme 32
146.58
5 years 32
Extreme 32
146.58
10 years 32
Extreme 32
146.58
Manager TitleAgeSince
Chief Executive Officer 31 2022-11-30
President 36 2020-07-31
Director of Finance/CFO 40 2023-09-30
Director TitleAgeSince
Director/Board Member 31 2019-09-30
Director/Board Member 84 2021-08-31
Director/Board Member 75 2021-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26
Montanova Capital LLC
OptionCompany 600,000 1.4361%
8/17/26 Exercice

Founder

50,404 0.1206%
8/17/26 Exercice

Founder

74,404 0.1781%
Change 5-day change 1-year change 3-year change Capi.($)
+3.73%+11.13% - - 6.01B
+4.28%+0.07%+52.75%+138.78% 1,258B
+2.13%+4.27%+51.21%+91.36% 679B
+0.68%+1.54%+33.83%+112.47% 518B
-0.34%+2.23%+43.31%+68.83% 390B
+1.38%+0.27%+72.42%+45.30% 367B
+0.52%+1.86%+31.06%+59.72% 307B
-0.43%+1.64%+6.54%+38.60% 293B
+1.04%-0.05%+45.29%+76.18% 252B
+1.46%-0.59%+42.48%+125.82% 210B
Average +0.93%+2.06%+42.10%+84.12% 428B
Weighted average by Cap. +0.59%+1.19%+45.37%+96.78%

Financials

2026 *2027 *
Net sales - 8.66M 7.73M 7.11M 6.45M 12.23M 812M 12.53M 85.07M 33.91M 434M 32.5M 31.8M 1.37B
Net income -104M -93.24M -85.8M -77.87M -148M -9.79B -151M -1.03B -409M -5.24B -392M -384M -16.51B -119M -106M -97.69M -88.66M -168M -11.15B -172M -1.17B -466M -5.97B -446M -437M -18.8B
Net Debt - -
Projected Income Statement - Annual - Veradermics, Incorporated
Logo Veradermics, Incorporated
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Employees
37
Date Price Change Volume
26-11-09 US$143.95 +3.73% 492,149
26-11-06 US$138.78 +7.92% 503,271
26-11-05 US$128.60 -5.79% 788,212
26-11-04 US$136.51 +2.17% 562,500
26-11-03 US$133.61 +3.15% 536,307
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Veradermics, Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
143.95USD
Average target price
173.00USD
Spread / Average Target
+20.18%
  1. Stock Market
  2. Stocks
  3. MANE Stock